SparingVision Conference Participation in H1 2026
Paris, 11 December 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, today announces the conferences its management team will participate in during the first half of 2026:
Investor and Industry Conferences:
JP Morgan 44th Annual Healthcare Conference, San Francisco, California, US – 12-15 January
Phacilitate Advanced Therapies Week, San Diego, California – 9 – 12 February
Scientific, Medical and Patient Associations Conferences:
Macula Society Annual Conference, San Diego, California, US – 25-28 February
Investing in Cures Summit, Boston, US – 6-7 March
Advanced Therapies, London, UK – 17-18 March
Retinal Therapeutics Innovation Summit 2026, Denver, Colorado, US – 1 May
ARVO (Association for Research in Vision and Ophthalmology), Denver, Colorado, US – 3-7 May
ASGCT (American Society of Gene and Cell Therapy), Boston, Massachusetts, US – 11-15 May
**ENDS**
NOTES TO EDITORS
Contacts:
Investors: Nathalie Trepo (nathalie.trepo@sparingvision.com)
Media: ICR Healthcare (sparingvision@icrhealthcare.com)
About SparingVision
SparingVision is a clinical-stage genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for blinding retinal diseases. Its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP) and geographic atrophy secondary to dry-AMD, two leading causes of blindness globally.
SparingVision is a spin-off from the Paris Vision Institute and backed by high-quality investors including 4BIO Capital, Adbio Partners, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital and Ysios Capital.
Visit www.sparingvision.com for more and follow us on LinkedIn and X (formerly Twitter) @SparingVision